4SC (VSC)

Business description

4SC is a Munich-based cancer biopharmaceutical company. Resminostat (HDAC inhibitor) is the lead candidate for cutaneous T-Cell lymphoma (pivotal study started in Q416). It has a second compound, 4SC-202 (Phase II) and a preclinical asset, 4SC-208. 4SC also has several partners including Yakult Honsha for resminostat in Japan.

Positive detailed analysis of Phase II trial data

QuickView | Pharmaceutical & healthcare | 09/11/2016

4SC has announced positive Phase II results from a more detailed analysis of the HCC Yakult Phase II trial data, which we believe could lead to further clinical development. It has also recently announced the sale of its immunology portfolio (Vidofludimus and a cytokine inhibitor), which further streamlines the company’s focus on its core business of epigenetics while retaining potential upside (via milestones and royalties). We increase our rNPV to €117m from €110m to reflect the increase in the potential of resminostat development in Japan.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.

Stock data

Market cap.€234.2m
Last close€7.640
High / Low (52 weeks)€8.4 / €2.3
Stock market listingDE
Forecast net cash (€m)36.5
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual47.555.9183.7
Relative *60.063.5169.3

* % Relative to local index

Company news

4SC

Thu, 16 Apr 2015 11:48:45 GMT

4SC

Sun, 09 Jul 2017 16:41:15 GMT

4SC

Wed, 08 Jul 2015 14:53:08 GMT

4SC

Thu, 14 Apr 2011 06:56:15 GMT

4SC

Fri, 05 Jan 2018 06:46:29 GMT